The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...

May 14, 2025 — Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study shows. The finding ...